Trending

#HeartFlow

Latest posts tagged with #HeartFlow on Bluesky

Latest Top
Trending

Posts tagged #HeartFlow

Preview
Medtech Heartflow IPOs, shares now available for Freedom clients – Oninvest The company raised $316.7 million, more than it had expected

🫀 AI-Powered Heart Imaging Firm #Heartflow (HTFL) Soars on IPO Debut

Proceeds will fund sales, marketing, and R&D. The IPO comes as insurers, including UnitedHealthcare, expand coverage for its tech starting Oct. 1. en.oninvest.com/article/medt...

0 0 0 0

Click Subscribe. #BainCapital #Heartflow #NasdaqDebut #InvestmentNews #TechStartups

0 0 0 0
Heartflow shares surge in Nasdaq debut Investing.com -- Shares of Heartflow opened at $28 on Friday, jumping over 47% above the initial public offering price of $19 per share in their Nasdaq debut. This opening price valued the medical technology company at $2.27 billion. On Thursday, Bain Capital-backed Heartflow announced it would sell nearly 16.7 million shares at $19 each in the IPO, which initially gave the company a market capitalization of approximately $1.59 billion before trading began. The Mountain View, California-based company had already previously increased the size of its IPO earlier this week to 16.7 million shares, priced between $17 and $18 each. This was an expansion from the original plans to offer 12.5 million shares at a price range of $15 to $17 per share.

Click Subscribe #Heartflow #Nasdaq #StockMarket #Investing #Finance

0 0 0 0
Heartflow opens for trading at $28, IPO priced at $19 Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #HeartFlow #IPO #StockMarket #Investing #Trading

0 0 0 0
Heartflow raises $316.7 million in US IPO as medtech listings attempt comeback By Ateev Bhandari and Pritam Biswas (Reuters) -Medical technology firm Heartflow said on Thursday it had raised $316.7 million in its U.S. initial public offering, setting the stage for its Nasdaq debut in another test of investor appetite for medical tech companies. The Mountain View, California-based company sold 16.67 million shares at $19 each, compared with a targeted range of $17 to $18 apiece. It upsized its offering and raised the proposed range earlier this week reflecting strong demand. The IPO valued the company at $1.54 billion. U.S. IPOs have picked up pace in a much-awaited recovery, as solid tech earnings and progress on trade deals have helped restore investor confidence. Strong recent debuts mark a reversal from early April, when uncertainty around U.S. President Donald Trump’s tariffs paused dealmaking. Heartflow’s stock will begin trading on the Nasdaq on Friday under the "HTFL" ticker symbol. The closing of the offering is expected on August 11. J.P. Morgan, Morgan Stanley and Piper Sandler are the lead underwriters for the offering. Following software firm Figma’s blowout debut last week, analysts expect companies with a compelling growth story to be welcomed by the public markets. "We expect Heartflow to be well received at launch, especially following Figma’s breakout success, which has helped reset sentiment toward high-growth names," IPOX CEO Josef Schuster said. Bain Capital-backed Heartflow leverages AI to create 3D models of the heart via a single specialized scan, improving detection and treatment of coronary artery disease (CAD). As AI gains widespread acceptance, companies embedding it into workflows for meaningful use cases are catching investor attention, with the technology powering gains across various Big Tech businesses. Heartflow’s revenue grew 39% for the quarter ended March 31 from a year earlier. Its platform to detect CAD was used in 132,000 patients in 2024. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

Click Subscribe #Medtech #Heartflow #IPO #Investment #StockMarket

0 0 0 0

Funding Raises: #CrusoeEnergySystems $225M Debt; #Heartflow $215M Series F; #BasePower $200M Series B; #Tailscale $160M Series C; #SandboxAQ $150M Series E; #Enpal €110 M Series E; #MeridaBiosciences $121M Series A; #Rescale $115M Series D; #Nuro $106M Series E

0 0 0 0